Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS value-based purchasing

This article was originally published in The Gray Sheet

Executive Summary

CMS report to Congress on value-based purchasing, released Nov. 26, suggests setting aside 2%-5% of hospital inpatient payments to use as a financial incentive to reward hospitals that meet or show substantial improvement for 20 quality measures. Congress asked the agency to come up with the plan in time to implement changes for fiscal year 2009 (1"The Gray Sheet" April 30, 2007, p. 12). The report outlines a three-year phase-in, building upon current pay-for-reporting requirements. Proposed measures relate to process-of-care, outcomes and patient satisfaction for treatment of heart attack, heart failure, pneumonia and surgical infection prevention. Industry says it will closely watch how Congress acts on the report to ensure that any future incentive-based program does not interfere with patient access to care

You may also be interested in...



Device Standardization Is Key In Value-Based Purchasing Environment – AHA

Device firms will need to further standardize their products as hospitals aim to meet new Medicare health care quality measures over the next few years, a hospital industry rep said April 25

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025543

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel